arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CERUS CORP

CERS
$2.34 ▲ +0.02 (+1.08%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CERUS CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $469.3M
Dividend Yield
Revenue Growth None
Op. Margin -3.2%
ROIC -2.7%
FCF / Share $-0.02
Trailing P/E
Price / Book 6.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$57.44M
↑ +7.0%
Net Income Profit after all expenses
$-2.94M
↑ +48.5%
Operating Margin Operating profit as % of sales
-3.2%
↓ -390.3% 21th
FCF / Share Free cash flow per share
$-0.02
↓ -4.2%
Long-Term Debt Long-term obligations
$20.00M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
22
Returns
26
Financial Health
45
Cash Quality
20

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters